Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Racura Oncology Reports Progress in CPACS Phase 1 Study of RC220 With Doxorubicin
Highlights
New Data Shared at Cardio-Oncology Summit
On 7 October 2026, Racura Oncology Ltd (ASX: RAC) said it had presented fresh data from its Cardioprotection & Anticancer Synergy (CPACS) Phase 1 study. The presentation took place at the 2026 Global Cardio-Oncology Summit in Williamsburg, Virginia. The talk covered the continuing assessment of RC220 given with doxorubicin to patients who have advanced solid tumours.
CPACS is a Phase 1 trial in two parts. It is open-label, runs at multiple centres, and has sites in Australia, Hong Kong and South Korea. The first part follows a Bayesian Optimal Interval design. Patients receive rising doses of intravenous RC220 with doxorubicin fixed at 60 mg/m². Safety and tolerability of the combination are the main things being measured. The study also looks at pharmacokinetics, early signs of anticancer activity and biomarkers of cardioprotection.
Safety Review Clears Higher Dose
According to the update, patients in the first cohort were given RC220 at 40 mg/m². They got through the set assessment window for dose-limiting toxicity (DLT) with no DLTs recorded. The Safety Review Committee then backed a step up to 80 mg/m², and patients are now being enrolled at that level.
Side effects linked to treatment in the first cohort were judged to be clinically manageable. Diarrhoea was reported more often than any other event. At Grade 3, the events seen were diarrhoea, fatigue, hypotension, lower platelet counts and neutropenia. There were no treatment-emergent adverse events at Grade 4 or Grade 5. A single serious case of Grade 3 diarrhoea arose during combination treatment, and it cleared up after medical management.
How RC220 Aims to Protect the Heart and Fight Cancer
RC220 is Racura's proprietary formulation of (E,E)-bisantrene. The company wants to find out whether pairing it with doxorubicin can keep or strengthen the anticancer effect while limiting the heart damage that anthracycline therapy can cause. The presentation referred to preclinical work in human cardiomyocytes and animal models. That work pointed to stronger anticancer activity and less anthracycline cardiotoxicity.
The presentation also outlined the next phase. Treatment will be expanded at the maximum tolerated combined dose in patients who have not previously received anthracyclines. This part is designed to study cardioprotection through functional, imaging and biomarker tests, and antitumour activity will continue to be tracked. Based on the market data supplied, shares in Racura Oncology Ltd (ASX: RAC) were quoted at AU$1.825, a rise of AU$0.054 or 3.107%.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au